AMGEN Competition

Bonds USA . 
Bond . AMGEN INC
031162DC1   67.81  3.77  5.89%   
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of AMGEN's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
66.6167.8169.01
Details
Intrinsic
Valuation
LowRealHigh
66.8568.0569.25
Details
Naive
Forecast
LowNextHigh
66.2867.4868.69
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
61.1666.0971.01
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as AMGEN. Your research has to be compared to or analyzed against AMGEN's peers to derive any actionable benefits. When done correctly, AMGEN's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in AMGEN INC.

AMGEN Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between AMGEN and its competitors represents the degree of relationship between the price movements of corresponding bonds. A correlation of about +1.0 implies that the price of AMGEN and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of AMGEN INC does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
COCO
+ 0.68
XNET
FIZZ
+ 0.51
ABTS
FIZZ
+ 0.39
BAOS
BOSC
+ 0.29
CNET
ABTS
+ 0.25
BAOS
COCO
+ 0.15
FIZZ
  
High negative correlations   
XNET
- 0.74
CNET
COCO
- 0.64
CNET
XNET
- 0.42
ABTS
BOSC
- 0.34
BAOS
BOSC
- 0.31
ABTS
FIZZ
- 0.28
XNET

Risk-Adjusted Indicators

There is a big difference between AMGEN Bond performing well and AMGEN Corporate Bond doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze AMGEN's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

AMGEN Competitive Analysis

The better you understand AMGEN competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, AMGEN's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across AMGEN's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
031162DC1 BAOS CNET ABTS BOSC FHBC XNET FIZZ COCO
 5.89 
 67.81 
AMGEN
 5.33 
 3.20 
Baosheng
 2.44 
 0.80 
CNET
 4.62 
 0.68 
Abits
 3.93 
 2.91 
BOS
 0.00 
 0.0001 
Fernhill
 4.37 
 1.75 
Xunlei
 0.42 
 45.67 
National
 3.13 
 28.03 
Vita
Market Volatility
(90 Days Market Risk)
Very steady
Unstable
Abnormally volatile
Abnormally volatile
Moderately volatile
Very steady
Very risky
Very steady
Very steady
Market Performance
(90 Days Performance)
Weak
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
OK
OK
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Average
Quite High
Average
Very Small
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Sell
Strong Sell
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Hold
Strong Sell
Hold
Hold
Strong Hold
Current Ratio
N/A
5.34
2.7
N/A
2.06
0.04
2.71
1.92
2.99
Net Asset
N/A
48.83 M
19.66 M
12.32 M
32.48 M
476.26 K
468.69 M
574.34 M
287.9 M
Profit Margin
N/A
-2.0
-0.29
N/A
0.0454
-0.87
0.0391
0.14
0.11
EBITDA
N/A
(2.41 M)
(3.58 M)
N/A
2.91 M
(666.75 K)
21.33 M
219.97 M
57.15 M
Operating Margin
N/A
3.1
-0.17
N/A
0.0367
-0.65
0.0032
0.18
0.17
Current Valuation
N/A
1.68 M
5.97 M
N/A
16.06 M
1.47 M
312.96 M
4.03 B
1.47 B
Price To Book
N/A
0.12
0.87
N/A
0.85
N/A
0.3
8.49
7.04
Retained Earnings
N/A
3.41 M
(53.52 M)
(77.89 M)
(67.13 M)
33 K
(146.94 M)
358.35 M
100.74 M
Current Asset
N/A
N/A
21.04 M
N/A
11.91 M
120 K
457.65 M
223.67 M
288.6 M
Beta
N/A
1.29
0.67
N/A
0.85
0.15
1.22
0.85
0.17
Number Of Employees
N/A
N/A
64
11
83
27
1.22 K
1.59 K
294
Shares Outstanding
N/A
1.53 M
7.2 M
N/A
5.75 M
N/A
64.38 M
93.54 M
56.68 M
Cash Flow From Operations
N/A
2.26 M
(316 K)
1.76 M
1.83 M
26.06 K
25.72 M
161.66 M
107.16 M
Total Debt
N/A
2.25 M
2.11 M
N/A
2.31 M
89.03 K
22.95 M
41.53 M
1.65 M
Return On Equity
N/A
-0.042
-0.69
N/A
0.11
N/A
0.0451
0.4
0.3
Z Score
N/A
N/A
N/A
N/A
N/A
9.3
N/A
N/A
N/A
Return On Asset
N/A
-0.0274
-0.22
N/A
0.0486
-1.08
-9.0E-4
0.22
0.17
Number Of Shares Shorted
N/A
270
2.56 K
N/A
16.16 K
N/A
21.27 K
1.92 M
6.49 M
Book Value Per Share
N/A
27.61
1.14
N/A
3.28
-213.86
5.02
5.51
3.7
Current Liabilities
N/A
N/A
7.37 M
N/A
6.67 M
42 K
76.74 M
75.61 M
251.25 M
Total Asset
N/A
48.83 M
19.66 M
12.32 M
32.48 M
476.26 K
468.69 M
574.34 M
287.9 M
Debt To Equity
N/A
0.012
0.12
N/A
0.1
N/A
0.11
0.15
0.17
Short Ratio
N/A
0.04
0.11
N/A
1.34
N/A
0.35
14.11
10.92
Target Price
N/A
N/A
27.7
N/A
N/A
N/A
12.0
47.0
30.44
Shares Owned By Institutions
N/A
0.01
N/A
N/A
15.99
N/A
4.82
24.33
76.53
Market Capitalization
N/A
5.29 M
5.9 M
N/A
16.73 M
1.47 M
112.66 M
4.27 B
1.59 B
Price To Earning
N/A
42.86
-2.43
N/A
20.83
N/A
15.85
27.96
15.97
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.02
1.07
Price To Sales
N/A
1.46
0.24
N/A
0.36
1.08
0.27
3.67
2.89
Net Income
N/A
(1.85 M)
(8.59 M)
(12.59 M)
2 M
202.85 K
14.27 M
142.16 M
46.63 M
Earnings Per Share
N/A
-1.2
-1.2
N/A
0.35
-48.72
0.22
1.82
0.91
Shares Owned By Insiders
N/A
41.13
17.94
N/A
14.19
N/A
18.92
74.83
13.12
Revenue
N/A
921.83 K
29.74 M
N/A
44.18 M
1.68 M
363.72 M
1.17 B
493.61 M
Working Capital
N/A
33.05 M
6.61 M
652.94 K
9.38 M
78 K
199.29 M
222.08 M
180.35 M
Cash And Equivalents
N/A
5.03 M
4.45 M
N/A
1.12 M
N/A
259.91 M
56.06 M
16.41 M
Cash Per Share
N/A
0.55
0.12
N/A
0.2
N/A
3.82
0.6
0.29
Gross Profit
N/A
1.83 M
(194 K)
N/A
9.06 M
705.64 K
141.44 M
396.79 M
103.36 M
Day Typical Price
67.81
3.31
0.8
0.68
2.97
1.0E-4
1.77
45.65
27.72
Accumulation Distribution
N/A
1526.73
468.34
215.32
7933.9
N/A
1380.2
1141.67
17528.85
Daily Balance Of Power
9.2 T
(0.56)
(0.50)
3.0
0.3667
0.0
(1.33)
0.3393
0.7944
Period Momentum Indicator
3.77
(0.18)
(0.02)
0.03
0.11
N/A
(0.08)
0.19
0.85
Rate Of Daily Change
1.06
0.95
0.98
1.05
1.04
1.0
0.96
1.0
1.03
Day Median Price
67.81
3.36
0.8
0.69
3.0
1.0E-4
1.78
45.64
27.57
Price Action Indicator
1.88
(0.25)
(0.01)
0.01
(0.04)
N/A
(0.07)
0.13
0.89
Relative Strength Index
52.19
45.57
45.35
43.66
57.54
N/A
56.09
41.83
61.34
Coefficient Of Variation
4244.72
(7,187)
(2,662)
(1,090)
2198.78
N/A
1045.68
(809.09)
719.96
Mean Deviation
0.7945
2.7
3.1
3.72
1.21
N/A
1.88
1.01
1.69
Jensen Alpha
0.0134
(0.05)
(0.18)
(0.45)
0.074
N/A
0.2324
(0.18)
0.3591
Total Risk Alpha
(0.01)
(0.13)
(0.26)
(0.56)
0.034
N/A
0.1897
(0.21)
0.3022
Sortino Ratio
0.0046
N/A
N/A
N/A
0.0458
N/A
0.074
N/A
0.1971
Downside Variance
1.13
N/A
N/A
N/A
1.89
N/A
10.24
N/A
3.12
Standard Deviation
1.2
3.43
4.19
4.78
1.9
N/A
2.72
1.38
2.68
Kurtosis
9.26
(0.37)
1.94
0.3344
15.57
N/A
2.25
2.06
13.1
Potential Upside
1.79
5.45
6.33
6.85
2.49
N/A
4.57
2.38
3.13
Treynor Ratio
0.05
0.092
(0.22)
(1.68)
0.411
N/A
0.1872
(0.69)
1.71
Maximum Drawdown
4.5
12.8
26.91
25.75
14.35
N/A
16.47
7.21
19.19
Variance
1.45
11.8
17.57
22.85
3.62
N/A
7.42
1.91
7.17
Market Risk Adjusted Performance
0.06
0.102
(0.21)
(1.67)
0.421
N/A
0.1972
(0.68)
1.72
Risk Adjusted Performance
0.0192
(0.0002)
(0.01)
(0.05)
0.0344
N/A
0.0657
(0.07)
0.0918
Skewness
1.77
0.0232
0.1688
(0.13)
2.88
N/A
(0.40)
0.9144
2.69
Semi Deviation
1.01
N/A
N/A
N/A
1.26
N/A
2.52
N/A
1.45
Information Ratio
0.004
(0.02)
(0.04)
(0.1)
0.0331
N/A
0.087
(0.14)
0.1301
Value At Risk
(1.91)
(5.90)
(5.05)
(7.69)
(2.15)
N/A
(4.37)
(2.29)
(3.13)
Expected Short fall
(0.81)
N/A
N/A
N/A
(1.46)
N/A
(2.26)
N/A
(2.04)
Downside Deviation
1.07
N/A
N/A
N/A
1.38
N/A
3.2
N/A
1.77
Semi Variance
1.02
N/A
N/A
N/A
1.59
N/A
6.36
N/A
2.09

AMGEN Competition Performance Charts

Five steps to successful analysis of AMGEN Competition

AMGEN's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by AMGEN INC in relation to its competition. AMGEN's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of AMGEN in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact AMGEN's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to AMGEN INC, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your AMGEN position

In addition to having AMGEN in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Hybrid Mix Funds Thematic Idea Now

Hybrid Mix Funds
Hybrid Mix Funds Theme
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out AMGEN Correlation with its peers.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between AMGEN's value and its price as these two are different measures arrived at by different means. Investors typically determine if AMGEN is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AMGEN's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY